Free Trial
NASDAQ:BIAF

bioAffinity Technologies Q1 2024 Earnings Report

bioAffinity Technologies logo
$0.28 -0.01 (-2.72%)
Closing price 04:00 PM Eastern
Extended Trading
$0.27 0.00 (-0.47%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

bioAffinity Technologies EPS Results

Actual EPS
-$0.21
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

bioAffinity Technologies Revenue Results

Actual Revenue
$2.41 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

bioAffinity Technologies Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, May 15, 2024
Conference Call Time
4:00PM ET

bioAffinity Technologies Earnings Headlines

Trump’s Bitcoin Reserve is No Accident…
How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum gains is closing faster than most people realize.
See More bioAffinity Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email.

About bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF), a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

View bioAffinity Technologies Profile

More Earnings Resources from MarketBeat